NCT05207371View on ClinicalTrials.gov

Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

October 1, 2022

Study Completion Date

December 1, 2025

Conditions
Cell TherapyNSCLC
Interventions
BIOLOGICAL

Biological

Intravenous injection of GAIA-102 alone or with Pembrolizumab (KEYTRUDA®︎)

Trial Locations (3)

812-8582

RECRUITING

Kyushu University Hospital, Fukuoka

802-8561

RECRUITING

Kitakyushu Municipal Medical Center, Kitakyushu

830-0011

RECRUITING

Kurume University Hospital, Kurume

Sponsors
All Listed Sponsors
lead

GAIA BioMedicine Inc.

INDUSTRY